Bank of America’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-9,839
| Closed | -$4K | – | 7699 |
|
|
2016
Q3 | $4K | Sell |
9,839
-10,517
| -52% | -$4.28K | ﹤0.01% | 6712 |
|
|
2016
Q2 | $9K | Buy |
20,356
+5,861
| +40% | +$2.59K | ﹤0.01% | 6550 |
|
|
2016
Q1 | $20K | Sell |
14,495
-26,439
| -65% | -$36.5K | ﹤0.01% | 6147 |
|
|
2015
Q4 | $60K | Buy |
40,934
+16,148
| +65% | +$23.7K | ﹤0.01% | 5972 |
|
|
2015
Q3 | $39K | Buy |
24,786
+4,316
| +21% | +$6.79K | ﹤0.01% | 6056 |
|
|
2015
Q2 | $35K | Sell |
20,470
-75
| -0.4% | -$128 | ﹤0.01% | 6122 |
|
|
2015
Q1 | $29K | Buy |
20,545
+6,500
| +46% | +$9.18K | ﹤0.01% | 5902 |
|
|
2014
Q4 | $21K | Sell |
14,045
-18,348
| -57% | -$27.4K | ﹤0.01% | 6783 |
|
|
2014
Q3 | $67K | Sell |
32,393
-42,412
| -57% | -$87.7K | ﹤0.01% | 6323 |
|
|
2014
Q2 | $228K | Sell |
74,805
-56,177
| -43% | -$171K | ﹤0.01% | 5435 |
|
|
2014
Q1 | $328K | Buy |
130,982
+97,370
| +290% | +$244K | ﹤0.01% | 4976 |
|
|
2013
Q4 | $167K | Buy |
33,612
+31,932
| +1,901% | +$159K | ﹤0.01% | 5748 |
|
|
2013
Q3 | $4K | Sell |
1,680
-323,921
| -99% | -$771K | ﹤0.01% | 7508 |
|
|
2013
Q2 | $723K | Buy |
+325,601
| New | +$723K | ﹤0.01% | 4379 |
|
Bank of America's RXII Position: Q4 2016 in Review
Bank of America sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 9,839 shares — an estimated $4K sold.
Bank of America first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $723K in Q2 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Bank of America reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Bank of America sold 9,839 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $4K.
- Bank of America first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Bank of America's GALENA BIOPHARMA INC COM position peaked at $723K in Q2 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Bank of America's 13F filing for Q4 2016, filed 14 Feb 2017.